Drug Trial Radar · NCT06158477
A Clinical Trial Evaluating JYP0035 Capsule Monotherapy in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
75
Planned (sponsor's estimate)
Start
Jan 1, 2024
Primary completion
Dec 1, 2026
Study completion Dec 1, 2027
Sponsor
- Lead sponsor
- Chengdu JOYO pharma Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Guangzhou JOYO Pharma Co., Ltd
- First posted
- Dec 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this Phase I clinical trial is to evaluate the safety, tolerability, and pharmacokinetic characteristics of the JYP0035 capsule in patients with advanced solid tumors. The main questions it aims to answer are: * What is the safety profile of JYP0035 when administered to these patients? * How does JYP0035 capsule behave in the body pharmacokinetically? Participants will: * Receive escalating doses of JYP0035 capsule during the dose-escalation phase (PART-1). * Continue with the identified dose in the dose-expansion phase (PART-2). As this is a single-arm study, there is no comparison group.
Conditions
- Advanced Solid Tumors
Interventions
JYP0035 Experimental Drug TreatmentDrug
Single dose intervention
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assess the adverse event rate of this clinical trialTime frame: From 8 weeks after the first administration up to week 52
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.